Access

News and Views

Nature Reviews Endocrinology 5, 297–299 (1 June 2009) | doi:10.1038/nrendo.2009.93

Diagnosis: Novel molecular signatures for adrenocortical carcinoma

Matthias J. Betz & Felix Beuschlein

The ability to distinguish between benign and malignant adrenocortical tumors requires great expertise; as a consequence, improvements in the early diagnosis, risk stratification and selection of effective therapies are urgently needed. Over the past decade, high-throughput techniques have emerged as powerful tools for the molecular and functional characterization of cancer cells.